Arcus Biosciences Inc (RCUS)
Payables turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cost of revenue | US$ in thousands | 125,000 | 110,000 | 76,129 | 45,553 | 28,806 |
| Payables | US$ in thousands | 17,000 | 20,000 | 10,000 | 15,682 | 4,704 |
| Payables turnover | 7.35 | 5.50 | 7.61 | 2.90 | 6.12 |
December 31, 2023 calculation
Payables turnover = Cost of revenue ÷ Payables
= $125,000K ÷ $17,000K
= 7.35
The payables turnover ratio for Arcus Biosciences Inc has been consistently reported as 0.00 for the past five years (from 2019 to 2023). A payables turnover ratio of 0.00 typically indicates that the company is not effectively managing its accounts payable. This could suggest that the company is not utilizing its suppliers' credit terms efficiently or may not have a significant amount of payables to manage in relation to its cost of goods sold.
A low or zero payables turnover ratio could also imply that the company may be paying its suppliers too quickly or has a high level of cash available to settle payables promptly. However, it is important to note that a payables turnover ratio of 0.00 may also signify potential issues with the accuracy or completeness of the financial data provided.
Further analysis of the company's payables management practices and financial operations would be necessary to understand the reasons behind the consistently low payables turnover ratio and to assess its impact on Arcus Biosciences Inc's overall financial health and performance.
Peer comparison
Dec 31, 2023